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Purpose—To evaluate the validity of the Patient-Reported Outcomes Measurement Information 
System (PROMIS) Physical Function measures in a diverse, population-based cancer sample.
Methods—Cancer patients 6–13 months post diagnosis (n=4,840) were recruited for the 
Measuring Your Health (MY-Health) study. Participants were diagnosed between 2010–2013 with 
non-Hodgkin lymphoma or cancers of the colorectum, lung, breast, uterus, cervix, or prostate. 
Four PROMIS Physical Function short forms (4a, 6b, 10a, and 16) were evaluated for validity and 
reliability across age and race-ethnicity groups. Covariates included gender, marital status, 
education level, cancer site and stage, comorbidities, and functional status.
Results—PROMIS Physical Function short forms showed high internal consistency (Cronbach’s 
α =0.92 – 0.96), convergent validity (Fatigue, Pain Interference, FACT Physical Well-Being all 
r≥0.68) and discriminant validity (unrelated domains all r≤0.3) across survey short forms, age, and 
race-ethnicity. Known group differences by demographic, clinical, and functional characteristics 
performed as hypothesized. Ceiling effects for higher-functioning individuals were identified on 
most forms.
Conclusions—This study provides strong evidence that PROMIS Physical Function measures 
are valid and reliable in multiple race-ethnicity and age groups. Researchers selecting specific 
PROMIS short forms should consider the degree of functional disability in their patient population 
to ensure that length and content are tailored to limit response burden.
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Introduction
Over half of cancer survivors are likely to experience significant physical limitations [1]. 
Decline in physical function is often associated with a cancer diagnosis and the ensuing 
initial treatment [2; 3], and such decline can have long-lasting effects extending past 
treatment and is associated with lower quality of life and increased risk of mortality [4].
Physical Function is a key patient-reported outcome (PRO) used to characterize and better 
understand overall health, level of physical disability and general well-being. Physical 
function is a foundation for many commonly-used general and cancer-specific (e.g., SF-36 
and FACT-G, respectively) PRO measures [5; 6] and the Patient-Reported Outcomes 
Measurement Information System® (PROMIS®) [7–9]. These measures provide a 
systematic report of functional well-being, similar to physician-rated performance status 
measures that are known to have low inter-rater reliability [10]. Physical function PROs 
offer a comprehensive assessment of body function, impact of disability on physical 
participation, activity level, and environmental and personal characteristics [11; 12] and 
incorporate the patient perspective.
PROMIS, a U.S. National Institutes of Health Common Fund initiative, has developed an 
extensive item response theory (IRT)-calibrated item bank, a collection of self-administered 
questions, and multiple short form questionnaires available to measure physical function. 
This physical function domain was developed to measure a full range of function on one 
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common standardized scale, minimizing ceiling and floor effects where the score is higher 
or lower than the survey can identify [12; 13], and has demonstrated conceptual validity and 
reliability [8; 14]. Initial validation of this domain in rheumatoid arthritis and osteoarthritis 
populations and normal aging cohorts showed that PROMIS physical function measures 
outperformed legacy instruments (i.e., the Health Assessment Questionnaire [HAQ]) [15]. 
Subsequent work validated this PROMIS physical function item bank in a more diverse 
general population sample [16]. The item banks were designed to allow customized short 
forms of variable length and item content to be created, yet yield comparable, standardized 
scores across the short forms [17]. However, the comparability of PROMIS Physical 
Function short forms in a community-based sample encompassing a broad range of age, 
disability level, and race-ethnicity has not been extensively tested.
Our study objectives were to evaluate (1) the applicability of the PROMIS physical function 
measures for a diverse sample of cancer patients, and (2) the psychometric performance of 
commonly-used PROMIS physical function short forms.
Methods
Recruitment
The Measuring Your Health (MY-Health) study recruited a population-based sample of 
cancer patients from four Surveillance, Epidemiology, and End Results (SEER) Program 
cancer registries (The Greater Bay Area Cancer Registry covering the San Francisco Bay 
and surrounding area, the Cancer Registry of Greater California covering the rest of the state 
except Los Angeles County, the Louisiana Tumor Registry, and the New Jersey State Cancer 
Registry). We stratified sampling by 4 race-ethnicity groups (Non-Hispanic White [NHW], 
Hispanic, Non-Hispanic Black [Black], Non-Hispanic Asian [Asian]) and 3 age groups (21–
49, 50–64, 65–84), based on base incidence rates at each registry. The study was approved 
by Institutional Review Boards at all participating institutions.
Population
Participants in this cohort were identified based on the following SEER eligibility criteria: 
21–84 years of age at diagnosis; diagnosed with one of seven cancers (prostate, colorectal, 
non-small cell lung, Non-Hodgkin lymphoma, female breast, uterine or cervical); no prior 
cancer diagnosis (except non-melanoma skin cancer); currently within 6–13 months of 
diagnosis and able to read English, Spanish, or Mandarin. Patients without cancer stage 
information, age, or race-ethnicity information were excluded from this analysis (N=662, 
figure 1) to ensure all known groups comparisons were done across a single uniform cohort.
MY-Health Survey
Survey items included self-reported sociodemographic characteristics, receipt of recent 
treatments, comorbidities, patient-reported outcomes and selected health behaviors. Pilot 
testing was conducted in 35 respondents to identify and correct any errors or unclear 
language and skip patterns in the survey. The SEER registry sites mailed a survey to eligible 
participants, with an additional Spanish and Mandarin Chinese translations sent to persons 
based on surname or made available upon request. Cover letters in the same language as the 
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survey were sent explaining the reason for the study and requesting participation. Along 
with a second mailing, phone follow-up was initiated for all non-responders after 3 weeks to 
encourage return of the survey. When contacted, participants were given the option to 
complete the survey over the phone in English, Spanish, or Mandarin Chinese. All Spanish 
and Mandarin translations of PROMIS items followed a strict translation protocol [18] and 
were done in coordination with the PROMIS Statistical Center at Northwestern University. 
Participants received a $30 gift card or check after completing the survey.
Demographic and Clinical Variables
We merged the patient survey data with SEER registry variables. SEER registry variables 
include: age, sex, date of cancer diagnosis, cancer type, and cancer stage. In addition we 
included the following self-reported survey variables: receipt of chemotherapy, radiation 
therapy, or hormonal therapy; surgery, comorbid conditions (number and type); education 
level; current employment status; annual income; marital status; insurance coverage; and 
whether the patient was born in the U.S. We used the following self-reported race-ethnicity 
categories (NHW, Black, Hispanic, Asian), created following U.S. Census (2010) 
classification algorithms [19]. When self-reported race-ethnicity was missing (<0.4% of 
patients) SEER registry information was used.
Patient-Reported Outcomes
We evaluated three established PROMIS Physical Function (PF) short form measures (PF 
4a, PF 6b, PF 10a, and custom 16-item form). PROMIS PF short forms are fixed 
assessments, administered either on paper or electronically. Two forms evaluated here (PF 
4a, PF 6b) are the physical function sub-scale of the PROMIS Adult Profile 29 v2 and 
PROMIS Adult Profile 43 v2, respectively [20]. We selected items for inclusion in the MY-
Health survey instrument based on either their inclusion in commonly used short forms, or 
their frequent selection in the online PROMIS Computer Adaptive Testing (CAT) format. 
We examined CAT item selection for two different patient groups (0.5 and 1.0 SD below the 
population mean). Convergent and discriminant validity (types of construct validity) were 
evaluated with respect to the following variables (each showing high internal consistency α 
in this cohort) [21]: Ability to Participate in Social Roles and Activities v1 (10 items, 
α=0.98); Emotional Distress – Anxiety (11 items, α=0.97); Emotional Distress—Depression 
(10 items, α=0.97); Fatigue (14 items, α=0.96); and Pain Interference (11 items, α=0.98). 
PROMIS measures are reported as T-scores (0–100 scale) with a mean of 50 and SD of 10. 
All PROMIS measures except Ability to Participate in Social Roles and Activities are 
normalized to the general US population [7]. High scores for Physical Function and Social 
Roles and Activity represent better functioning and high scores for the symptoms represent 
greater symptom burden. To address convergent and discriminant validity, we also 
administered the 7-item FACT Physical Well-Being (PWB) subscale (α=0.84) [5]. 
Spirituality, comprised of two sub-domains (faith and peace) measured by the FACIT-SP-12 
v4 (α=0.85) [22]; a 5-item financial burden subscale from the PSQ-III (α=0.83) [23]; an 8-
item acculturation scale for U.S. immigrants (α=0.94) [24]; To address known groups 
validity, questions on the use of assistive devices, a single-item Patient Self-Report ECOG 
Performance Status Scale used in cancer clinical trials to assess disease impact on daily 
living abilities [25], comorbid medical conditions (asthma, COPD, arthritis, and overall 
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number), physical activity, stage of disease, cancer site, and demographic variables were 
included. Hypotheses are described below.
Reliability and Validity Testing
We used standard psychometric procedures to evaluate reliability and validity [26] of each 
PROMIS PF short form across 3 age (21–49, 50–64, 65–84) and 4 race-ethnicity (NHW, 
Black, Hispanic, Asian) groups. We evaluated overall and item-level performance. We 
estimated internal consistency using Cronbach’s Coefficient alpha, with α > 0.70 and α > 
0.90 the thresholds for reliable group and individual level (inter-individual comparisons at a 
single time point) measurement, respectively. For structural validity, we evaluated 
unidimensionality of the PROMIS PF short forms using factor analysis methods, with a 
mean- and variance-adjusted weighted least square (WLSMV) estimator. Goodness of model 
fit indicators and thresholds included: comparative fit index (CFI), and the Tucker-Lewis 
Index (TLI). We tested multiple types of construct validity across age and race-ethnicity 
groups. We examined convergent and discriminant construct validity by calculating Pearson 
correlations between Physical Function and other administered scales. The PROMIS PF 
short forms were expected to be positively correlated with social role participation and 
another measure of physical function (the FACT - Physical Wellbeing subscale) and 
negatively correlated with symptom severity (e.g., more fatigue or pain) and weakly 
correlated other non-physical function measures (e.g., FACIT Spirituality, Financial Burden, 
and Acculturation). We used chi-square tests to evaluate known-group validity of expected a 
priori differences in physical function (all forms), for the total sample. Specific variables, 
hypotheses and supporting citations are described in table 5, any minimally important 
differences between race-ethnicity or age groups (PROMIS physical function T-score ≥4, a 
meaningful important score difference [27], are also identified). Factor analysis was 
conducted using Mplus (version 7.1, Los Angeles, CA); all other analyses were conducted 
using SAS (v. 9.3, SAS Institute, Cary, NC).
Results
Overall, participants in the MY-Health cohort are demographically and clinically diverse, 
important for establishing generalizability to other cancer populations (Table 1). Non-White 
participants comprised 57% percent of the total cohort and 59% of participants were under 
65 years of age. Eighteen percent of the cohort reported less than a high school education 
(Hispanics, 37%; Blacks, 22%; and Asians, 14%), 15% and 50% of the cohort reported 
household income levels under $60,000. Thirty percent were not born in the U.S., and 9% of 
surveys were completed in Spanish or Mandarin Chinese. Cancer incidence by type ranged 
from cervix (3%) to breast (30%); 12% of patients were diagnosed with stage IV cancer; and 
about half reported the receipt of chemotherapy (48%).
This cohort reported a mean PROMIS Physical Function score (using the PF 16-item short 
form score) of 44.9 (Table 2), one half standard deviation lower than the overall U.S. 
population mean. Mean differences in PROMIS PF short form scores and the 16-item MY-
Health form ranged from 0.05 (PF 10a) to 0.80 points (PF 4a), all well-within the mean 
standard error of measurement (2.2 – 3.9 points). These differences remained consistent 
Jensen et al. Page 5













across age and race-ethnicity groups. Reliability of all PROMIS Physical Function short 
forms was high (α=0.92–0.96, Table 2), and remained >0 .90 when restricted to subgroups 
based on age and race/ethnic groups (not shown in tables). Floor effects were minimal across 
all forms, but ceiling effects were evident in PF 4a (34.5%) and PF 6a (25%).
For structural validity, confirmatory factor analysis for a one factor model fit to all 16 items 
generally showed good fit (CFI and TLI = 0.99). Exploratory factor analysis identified one 
strong factor (Eigenvalue=12.7) and high factor loadings (>0.6) for all items. A second, 
highly correlated factor (r=0.83) was identified for items that ask about self-care actions 
(e.g., wash and dry your body, shampoo your hair) that are only found on the PF 10a (Table 
3).
For convergent and discriminant validity, physical function was correlated with other PRO 
domains as hypothesized (see Table 4), and consistent with previous literature. There were 
strong correlations (r≥0.67) with ability to participate in social roles, fatigue, pain, and 
functioning on the FACT-G PWB scale. The domain was moderately associated (r=−0.38 to 
−0.50) with depression, anxiety, and sleep disturbance scores. Physical function showed 
weak to moderate correlations (r≤0.26) with spirituality, financial burden, and acculturation.
Known-groups testing confirmed our a priori hypothesis about differences in physical 
function (Table 5). Only two sub-group comparisons (cancer site, and performance status) 
showed age and race-ethnic differences that were 4 or more points higher or lower than the 
reference groups. Among cancer clinical variables, cancer patients diagnosed with advanced 
cancer and those who received chemotherapy both reported significantly lower physical 
function scores (−4.40 and −5.35 points, respectively). Of all cancer types, lung cancer 
patients had the lowest mean physical function scores (39.1), while men with prostate cancer 
reported the highest mean scores (49.6).
Self-reported comorbidities were associated with large decreases in physical function by 
both the number of other conditions reported and whether COPD or asthma was reported. As 
expected, the largest differences in physical function (13 points, p<0.001) were found if a 
person indicated they had any trouble walking. These findings also were consistent when 
physical function was evaluated by ECOG performance status, covering a large range of 
disability. Overall each decrease in performance status level (normal, some symptoms, 
<50% bed rest, >50% bed rest), was also a large, statistically significant decrease in physical 
function, while the scores and standard deviations were consistent across each level (Figure 
2).
We found that scores near the floor and ceiling of this domain were similar across all short 
forms examined. Groups anticipated to be very low functioning near the floor of this domain 
(>50% bed rest) reported similar scores (<0.5 of a point) across all physical function short 
forms. The highest-functioning group (reported vigorous activity 5 or more times a week) 
had a two-point mean difference between 4-item and the full 16-item measures, still within 
the standard error of measurement for both forms (data not shown).
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This study demonstrated the validity and reliability of PROMIS Physical Function short 
forms in a socio-demographically diverse, population-based cohort of cancer patients. We 
found that scores across all short forms performed consistently across race-ethnic and age 
groups. Reliability and validity criteria were met for race-ethnic and age groups across all 
tested physical function forms, providing strong evidence that these measures are accurate, 
precise, and comparable in a diverse cohort of cancer patients.
Previous work validating the PROMIS Physical Function bank suggested that, like virtually 
all extant measures of self-reported physical function, there may be content gaps at the 
ceiling of the measure (i.e., items that can measure high levels of physical function and 
athleticism) [28]. We observed similar findings in this lower physical functioning cohort. 
Ceiling effects were identified for all physical function short forms in use, and were notably 
higher in the 4-item form; floor effects were minimal across all short forms. This suggests 
that when physical function short forms are administered in higher-functioning populations a 
full standard deviation above U.S. population (60) or higher, custom item selection for 
higher functioning individuals becomes increasingly important to ensure accurate 
measurement. Assessment administration method (fixed item short form vs. CAT) should 
also be considered in selection, as recent studies show that CAT administration of the 
PROMIS Physical Function item bank in both clinical and general population samples 
reduces this ceiling effect [29; 30] and new items have been added that directly address 
ceiling and floor effects [31; 32]. However, when the administration of a fixed short form is 
necessary, our findings suggest that increasing short form length (i.e., 6b or higher) reduces 
ceiling effects.
Factor analyses suggest that the 4 items measuring self-care (e.g., washing hair) may form a 
separate factor; however, the high correlations with the other physical function items support 
the unidimensionality of the PROMIS Physical Function item bank. This replicates results 
from the initial validation and calibration of the full physical function item bank 
recommending a parsimonious one factor solution [15; 30]. Questions focusing on self-care 
actions may not be as relevant for a general ambulatory cancer population. Because these 4 
self-care items are administered on one short form (10a), understanding the clinical needs of 
the population is important prior to a short-form selection. The PROMIS physical function 
domain has addressed some of these issues, offering tailored assessment for upper extremity 
function and use of mobility aids [33], increasing flexibility and relevance of this domain 
across a broad range of physical function.
PROMIS currently offers a wide range of physical function short forms, geared toward 
different patient groups and functional ability. This study confirmed the expectation that 
longer forms reduce the standard error of measurement (i.e., reliability increased with longer 
short forms). However, the 6b form reported better internal consistency than the 10a form, 
with a smaller ceiling effect than that identified in the 4a form. While all forms performed 
well, the results presented here suggest diminishing gains in precision in the 10a and 16 
forms (but lower floor and ceiling effects) compared to the 6b form in this population. 
Recent work has confirmed these findings [12; 15; 28; 30–32], extending the range of items 
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at the floor and the ceiling When high precision is necessary in research settings, the 
PROMIS PF-20 (an extension of the PF 10a form tested here) is coming into broad use as a 
replacement for the traditional HAQ-DI. It has been found to be more sensitive to change 
and requires smaller sample sizes without increasing questionnaire burden.
This study has a few notable strengths and limitations. This population is limited to 
participants diagnosed with cancer, measuring average or lower physical function, limiting 
the generalizability of these findings to very-high functioning individuals. However this 
population is also a strength of this study as the broad cancer inclusion criteria (7 cancers, all 
stages) allowed for a wide range of disability levels encountered in many medical 
conditions. In addition, by using a large, community-based patient cohort with verified 
diagnoses and clinical characteristics, this study extends previous work that reported only 
self-report illness status or small clinical samples to a diverse community-based cohort. 
Furthermore, PROMIS measures are designed to provide cross-condition comparisons using 
a standard, non-cancer specific scale of measurement. Therefore these findings are relevant 
and applicable across a full range of physical function from individuals with little to no 
impairment to those on bed rest.
An additional limitation regarding the sample is the relatively low participation rate of 
eligible patients. The overall response rate (this includes those unable to be contacted, died 
or later deemed ineligible) for this study was approximately 31%, higher among those able 
to be reached by study staff (53%). While low these rates are consistent with large, SEER-
based surveys of recently diagnosed cancer patients [34–36]. Additionally, this study 
specifically targeted and oversampled patients from under-represented populations and 
patients with metastatic disease. As a result, these groups reported lower response rates (5–
7% lower), than younger, white, or non-metastatic study participants.
A third limitation is that this paper focused on reliability and validity of common short 
forms across age and race-ethnic groups using classical test theory methods. Further work 
evaluating this domain with psychometric criteria such as differential item function (DIF) 
that identifies systematic differences in how groups respond to specific items is an important 
and complementary effort, currently underway. For example, past evaluations have 
determined that DIF by age group may be especially important for physical function [37].
Finally, it is important to note that while clinical characteristics about cancer type and stage 
were reported from the registry, treatment and comorbidity information was self-reported by 
patients. These two variables may be less accurate than other methods of data collection, 
such as medical record abstraction, and can be associated with an information bias. 
However, these are standard questions used in other national cancer surveys [34]. Therefore 
we feel confident this information is sufficient to evaluate known group validity.
The final study limitation is the inability to evaluate the PF 8b, an 8-item PROMIS PF short 
form, because we did not administer all 8 items in this survey. Therefore, these findings 
cannot be extended to this short form. However, the 6b short form entirely overlaps the 8b, 
suggesting it will perform as well, if not better than the 6b.
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This study confirms the validity and reliability of the PROMIS Physical Function item back 
and short forms across a wide range of age and race-ethnic groups reflecting the extensive 
diversity of the U.S. population. It shows that these short forms can precisely measure 
meaningful group differences in cancer patient populations, accurately reflecting both 
disease burden and comorbidities across all versions. While some isolated measurement 
issues were identified, and should be considered when selecting a short form, their impact on 
the normalized scoring is minimal.
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